DOCSLIB.ORG

'Jfu: 'Jwenty C:::Mnth Florida, U.S.A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
'Jfu: 'Jwenty C:::Mnth Florida, U.S.A _J L m§ 15. Prof. David Bates (1995) Professor of Neurology University of Newcastle-upon- Tyne, U.K. 16. Prof. W.G. Bradley (1996) Chairman & Professor of Neurology, University of Miami School of Medicine, 'Jfu: 'Jwenty c:::Mnth Florida, U.S.A. 17. Prof. Robert C Griggs (1997) Chairman and Neurologist-in-Chief, University of Rochester, New York, U.S.A. 18. Prof. M.R. Trimble (1998) 'J ~ ~ilnlrJaian Raymond Way Professor of Behavioural Neurology, Institute of Neurology, Queen Square, London, U.K. 19. Prof. Sid Gilman (1999) Chairman & Professor of Neurology University of Michigan, Michigan, U.S.A. 20. Prof. Timothy A. Pedley (2000) Henry & Lucy Moses Professor of Neurology & Chairman, Dept. of Neurology, Columbia University New York, U.S.A. Prof. J.C. Morris 21. Prof. RSJ Frackowiak (2001) Professor of Neurology, National Hospital Dr. Morris received his B.A. from Ohio Wesleyan University. After receiving his MD from Queen Square, London, U.K the UniversiLy of Rochester School o( Medicine and Dentistry i;1 Rochester, NY, in 1974, he 22. Prof. Stanley Fahn (2002) completed his internship at San Francisco General Hospital before joining a private practice Houston Merritt Professor of Neurology as a family physidan in Fairbanks, Alaska (1975-76) and then directing the Emergency Columbia University, New York, U.S.A. Room at Carlsbad Regional Medical Cenb·e In New Mexi o (1976-77). Dr. Morris received 23. Prof. Jeffrey L. Cummings (2003) Augustus Rose Professor of Neurology, board ccrtliication in Internal Medicine and Neu,rology after returning to OJ1io to complete Psychiatry & Biobehavioral Sciences, UCLA residency programs in medicine (Akron General Medical Centre) and neurology School of Medicine, Los Angeles, CA,U.S.A. (Cleveland Metropolitan General Hospital). He joined Washington University School of 24. Prof. J.P. Molu, (2004) Medicine in 1982 as a postdoctoral fellow in neuropharmacology and as an Inshuctor in Daniel Sciarra Professor of Clinical Neurology in 1983. Neurology, Director, Doris & Stanley Tananbaum Stroke Center, Neurological Dr. Morris was nan1cd as the Ha1-vcy A. and Dorismae Hacker Fi-iedman Professor of .' , Institute, Columbia-Presbyterian Medical Neurology in 1998 and Distinguished Pi·ofessor in 2003. He is, in addition, Professor o( Center, New York, U.S.A. Pathology and Immunology, Professor oi Physical ·n1erapy, and Director of the Memory 25. Prof. Anne B Young, (2005) and Agini, Project, and the Centre for Agin at Washington University. He also is the Julieanne Dom Professor of Neurology Director and Pri.ncipa !Investigator of the Alzheimer's Disease Research Centre. Harvard Medical School, Boston, & Chief of Neurology Services at Massachusetts Dr. Morris is the Principal Investigator of two projects, "Healthy Aging and Senile General Hospital, U.S.A. Dementia," and "Antecedent Biomarkers for AD: The Adult Children Study" and the centre 26. Prof. John R Hodges, (2006) grant, '1Alzheimer s Disease Research Centre,• all funded by the National Institute on Aging Professor of Behavioural Neurology & (NlA). He directs Washington University's Harvey A. Friedman Centre for Aging. In the Head MRC Cognition & Brain Sciences Unit, University Department of Neurology, Medical Scho l's Department of Neurology, Dr. Morris serves as Head of th.e Dementia and Aging Section. Dr. Morris has over 250 publications to his credit and has edited the fi.rst and Cambridge, UK. 1 27. Prof. Stanley B. Prusiner, ( 2007) second. editions of the Handbook of Dementing DlnC>se.s. He has received many honours February 14 \ 2009 Nobel Laureate & Professor of Neurology and induding the Lifetime Achievement Award from the Alzheimer's Association (2004), and ITC Park Sheraton Hotel and Towers Biochemistry, University of California, the Potamkin Prize for Research in Pick's, Alzheimer's, and Related Disease from the San Francisco, U.S.A. Chennai American Academy of Neurology (2005). 28. Steven C. Schachter, (2008) Professor of Neurology at Harvard Medical School in Boston, Massachusetts, U.S.A. ~ ~______,a.......'--------'----------------,President-Elect, American Epi lcps.y Society 7 i __J L The following eminent neurologists have visited IndiBMa The Twenty Ninth TS Srinivasan millennium to encompass apart from privileged to now be affiliated with youngest son of Shrt. TV Sundaram. and delivered the T.5. Sru1ivasan Endowment Orations begbming1980. Endowment Oration will be comm.unity level care, focussed the TN Dr. MGR Medical University Iyengar, Shrl.T.S. Srinivasan began 1. Prof. W.B. Mathews (1980) delivered by Professor education for neuroscience in 2008 and will soon be launching a his career with the TVS Group Professor of Oinical Neurology J.C.Morris, Harvey A. & professionals, high quality research range of interdisciplinary programs companies, and was noted for his Oxford University, U.K. Dorismae Hacker Freidman in clinical neurosciences and most leading to the PhD in innovative ideas. He not only 2. Prof. Donald W Baxter (1981) Professor of Neurology, recently, the development of health Neuropsychiatry, Biomedical modernised the services and Chairman of the Department of Neurology and Washington University, St. Louis. policyfor neurosciences. Neuroscience and Disability. These facilities of the Group companies , Neurosurgery, McGill University, Canada. Tl1e oration and award are milestones l1ave enhanced our but also guided their entrance into 3, Prof.SirJohnNWalton(1982) The TS Srinivasan Centre is the Professor of Neurology sponsored by the TS Srinivasan flagship academic centre in The credibility as an academic the manufacture of critical University of Newcastle- upon -Tyne, U.K. Charitable Trust through the TS Institute of Neurological Sciences, department and emboldened us to automotive components. His 4. Prof.J.A Simpson (1983) Srinivasan Centre for Clinical Voluntary Health Services Hospital offer world class training to a range dynamism and enterprise cnlm:lnated ConsultantinNeurology University of Glasgow, U.K. Neurosciences & Health Policy at (VHS). Founded by Prof. KS Sanjivi, of Indian professionals across in the establishment of several 5. Prof.John BFoster(1984) Voluntary Health Services a giant in community health. VHS is disciplines. manufacturlng units in collaboration leading international Consultant in Neurology Medical Centre, Taramani, renowned as a non-proftt hospital. We have also in the past two years with University of Newcastle-upon-Tyne, Chennai -600113. that provides care for people from demonstrated our determination to organisations. His foresight was also ChiefofNeurology The TS Srinivasan Oration is poorer sections of society and contribute to the development of responsible for the manufacture of Newcastle General Hospital, U.K. 6. Prof.J.W. Lance(1985) iconic in its conceptualisation. It manages a host of important evidence based health policy in India. powered two-wheelers for personal transportation. Professor of Neurology espouses the fl.nest traditions community level projects in its Our work in epilepsy in collaboration University of New South Wales and values of supreme quality, capacity as a mother NGO. with the Indian Epilepsy Association From an early age, Shrl Srinivasan Sydney, Australia. selfless endeavour and high The TS Srinivasan Centre has an and the Inten1ational League Against was the embodiment of compassion. 7. Prof. Lewis PRowland (1986) aspiration that inspire young Epilepsy has resulted in the He earned the love and affection of Henry & Lucy Moses Professor of Neurology & active group of research fellows who Chairman, Department of Neurology, a scientific professionals and work in diverse fields of development of novel clinical and his employees with his humane Columbia University, New York, U.S.A. doctors, while informing, neuroscience- epidemiology, health policy concept "Disabling approach and unique empathy • a 8. Prof. Kevin Barron (1988) educating and empowering lay outcomes research, clinical trials, Epilepsy". These contributions to wisdom that brought the humblest Professor&; Chairman Department of Neurology, Albany Medical intelligentsia. That the most imaging and patient-centred epilepsy have been recognised sufferer to his door. He was fully senior, distinguished and internationally and nat ionally. We committed to alleviating the College of Union University, New York, U.S.A. research & health policy Prof. Jean Aicardi (1989) sincerely hope that they wlll serve as sufferings of his fellow human 9· decorated neurologists world­ development. The fellowships hosted Director of Paediatric Neurology ,",.• over have graced this program, by the centre have included those agents of change, thus benefiting beings. Monetary considerations Hospital for Infants and Children, Paris, France. ·,.' j and that it has repeatedly supported by prestigious many thousand people around the never stood in the way ofhis ful:Olling 10. Prof. C.D. Marsden (1990) Professor of Neurology received mention in the green organisations and International globe. We are now embarking on a this commitment. journal "Neurology", the official systematic program of education, National Hospilal,Queen Squai-e, London, U.K. collaborations with renowned Shrl. TS Srinivasan's life was devoted 11. Prof. Thomas Brandt(1991) organ of the American Academy research concept and health policy universities and research groups. For to advancement and improvement, Professor & Head., Dept. of Neurology of Neurology, is testimony to the ftve years we have taught the clinical development targeting disabling not
Load more

Recommended publications
  • Anne Buckingham Young
    BK-SFN-NEUROSCIENCE-131211-13_Young.indd 554 17/04/14 2:26 PM Anne Buckingham Young BORN: Evanston, Illinois December 30, 1947 EDUCATION: Vassar College, Summa Cum Laude, AB (1969) Johns Hopkins University Medical School, MD (1973) Johns Hopkins University Medical School, PhD (1974) APPOINTMENTS: Assistant, Full Professor of Neurology, University of Michigan (1978–1991) Julieanne Dorn Professor of Neurology, Harvard Medical School (1991–2012) Chief, Neurology Service, Massachusetts General Hospital (1991–2012) Distinguished Julieanne Dorn Professor of Neurology, Harvard Medical School (2012–present) HONORS AND AWARDS (SELECTED): Member, Institute of Medicine (1994) Fellow, American Academy of Arts and Sciences (1995) Dean’s Award for Support and Advancement of Women Faculty, Harvard Medical School (1999) Marion Spence Faye Award for Women in Medicine (2001) President, American Neurological Association (2001–2003) President, Society for Neuroscience (2003–2004) Fellow, Royal College of Physicians, England (2005) Milton Wexler Award, Hereditary Disease Foundation (2006) Johns Hopkins Medical School Distinguished Alumni Award (2007) Vassar College Distinguished Alumni Award (2010) As a graduate student, Young provided the first biochemical evidence of glutamate as a neurotransmitter of the cerebellar granule cells. She developed biochemical techniques to measure inhibitory amino acid neurotransmitter receptors in the mammalian brain and spinal cord. As a faculty member at the University of Michigan, Young and her late husband (John B. Penney, Jr.) established the first biochemical data that glutamate was the neurotransmitter of the corticostriatal, corticobulbar, and corticospinal pathways. They developed film-based techniques for quantitative receptor autoradiography. They also provided evidence for their most widely cited model of basal ganglia function.
    [Show full text]
  • MATHEW MARTOMA, Defendant. No. 12
    Case 1:12-cr-00973-PGG Document 271 Filed 02/27/14 Page 1 of 45 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK UNITED STATES OF AMERICA, No. 12-cr-00973 (PGG) -against- ECF Case MATHEW MARTOMA, ORAL ARGUMENT REQUESTED Defendant. DEFENDANT MATHEW MARTOMA’S MEMORANDUM OF LAW IN SUPPORT OF HIS RENEWED MOTION FOR A JUDGMENT OF ACQUITTAL OR, ALTERNATIVELY, FOR A NEW TRIAL GOODWIN PROCTER LLP Richard M. Strassberg (RS5141) John O. Farley (JF4402) Daniel Roeser (DR2380) The New York Times Building 620 Eighth Avenue New York, New York 10018 (212) 813-8800 Roberto M. Braceras (RB2470) 53 State Street Boston, Massachusetts 02109 (617) 570-1000 Attorneys for Defendant Mathew Martoma February 27, 2014 Case 1:12-cr-00973-PGG Document 271 Filed 02/27/14 Page 2 of 45 TABLE OF CONTENTS Page PRELIMINARY STATEMENT .................................................................................................... 1 BACKGROUND ............................................................................................................................ 3 ARGUMENT .................................................................................................................................. 4 I. THE COURT SHOULD ENTER A JUDGMENT OF ACQUITTAL ON ALL COUNTS PURSUANT TO FEDERAL RULE OF CRIMINAL PROCEDURE 29. ............................................................................................................... 4 A. This Court Should Enter A Judgment Of Acquittal On The Substantive Counts Of Insider Trading. ....................................................................................
    [Show full text]
  • Kaplan V. S.A.C. Capital Advisors, L.P. 12-CV-09350-Joint Consolidated
    Case 1:12-cv-09350-VM-KNF Document 127 Filed 03/31/14 Page 1 of 185 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK - - - - - - - - - - -- - - - - - - - - - - - - - - - - - - - - - - - - - - - - x : DAVID E. KAPLAN, MICHAEL S. ALLEN, CHI-PIN HSU, GARY W. MUENSTERMAN, FRED M. ROSS, MICHAEL CAHILL, JOHN P. CONNOLLY, JOHN M. GOULD, CAROLINE P. GOULD, GREG : KAPPES, DEEANN LEMMERLING, LUC : No. 12 Civ. 9350 (VM) (KNF) LEMMERLING, GARRY LEONARD, DAVID : (All Actions) LINDSAY, RICHARD LLOYD, GLEN LOCHMUELLER, STEPHEN W. MAMBER, JAMES C. MCGOWAN, CHRIS MITCHEM, BRIDGET : JURY TRIAL DEMANDED MONRAD, CHRISTIAN MONRAD, BENJAMIN MONRAD, JOSEPH F. MORGAN, JIM MOSER, STEVEN R. OLSON, LAWSON PHILLIPS, : ECF CASE SEYMOND PON, PAT A. SANYE, RONALD J. SANYE, PATRICIA TRACY, LINH TU, RAJ VADDI, JOHN WOLFF, and RHONDA WOLFF, Individually and on Behalf of All Others Similarly Situated, Plaintiffs, - against - S.A.C. CAPITAL ADVISORS, L.P., S.A.C. CAPITAL ADVISORS, INC., CR INTRINSIC INVESTORS, LLC, CR INTRINSIC INVESTMENTS, LLC, S.A.C. CAPITAL ADVISORS, LLC, S.A.C. CAPITAL ASSOCIATES, LLC, S.A.C. INTERNATIONAL EQUITIES, LLC, S.A.C. SELECT FUND, LLC, STEVEN A. COHEN, MATHEW MARTOMA, and SIDNEY GILMAN, Defendants. - - - - - - - - - - -- - - - - - - - - - - - - - - - - - - - - - - - - - - - - x (caption continued . ) JOINT CONSOLIDATED AMENDED CLASS ACTION COMPLAINT Case 1:12-cv-09350-VM-KNF Document 127 Filed 03/31/14 Page 2 of 185 (. caption continued) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x : BIRMINGHAM RETIREMENT AND RELIEF : SYSTEM and KBC ASSET MANAGEMENT NV, : Individually and on Behalf of All Others Similarly : Situated, : No. 13 Civ. 2459 (VM) (KNF) Plaintiffs, : - against - : JURY TRIAL DEMANDED : S.A.C. CAPITAL ADVISORS, L.P., S.A.C. CAPITAL : ADVISORS, INC., CR INTRINSIC INVESTORS, : ECF CASE LLC, CR INTRINSIC INVESTMENTS, LLC, S.A.C.
    [Show full text]
  • ACT-AD and FDA Focus on Evaluating Clinical Effectiveness in Early Alzheimer's Disease
    ACT-AD and FDA Focus on Evaluating Clinical Effectiveness in Early Alzheimer’s Disease -- Scientists and FDA discuss options to guide research and drug availability -- Rockville, MD, July 21, 2009 – The ACT-AD (Accelerate Cure/Treatments for Alzheimer's Disease) Coalition today hosted the second in a series of defining meetings with a senior representative from the US. Food and Drug Administration (FDA), leading scientists, drug developers and AD advocates to address critical issues affecting the review and approval of new therapies for Alzheimer’s disease (AD). Participants focused on the FDA’s current standards for defining clinical meaningfulness, especially in Mild Cognitive Impairment/Early Alzheimer’s Disease (MCI/EAD); explored potential alternatives to global or functional assessments in these patients; reviewed the need for better trial design; and considered learnings on MCI/EAD from other regulatory agencies. The meeting was coordinated by ACT-AD, a coalition of national organizations seeking to accelerate development of potential cures and treatments for AD, and co-hosted by The Alzheimer’s Association and Leaders Engaged in Alzheimer’s Disease (LEAD). “Over the past three years, ACT-AD’s member organizations and our partners have coordinated a series of historic meetings with the FDA that have brought expert consensus on key Alzheimer’s issues to the Agency and built a momentum of collaboration that today resulted in concrete progress toward a workable definition of clinical effectiveness in early stages of the disease. And just in time,” said Daniel Perry, chair of the ACT-AD Coalition. “Literally each day brings greater hope for breakthroughs, but it also brings greater urgency as we continue to fight this disease individually and as a nation.
    [Show full text]
  • Handbook of the Cerebellum and Cerebellar Disorders
    Handbook of the Cerebellum and Cerebellar Disorders Mario Manto • Donna L. Gruol Jeremy D. Schmahmann Noriyuki Koibuchi • Ferdinando Rossi Editors Handbook of the Cerebellum and Cerebellar Disorders With 545 Figures and 69 Tables Editors Mario Manto Donna L. Gruol Unite´ d’Etude du Mouvement (UEM) Molecular and Integrative Neuroscience FNRS, Neurologie ULB Erasme Department (MIND) Bruxelles, Belgium The Scripps Research Institute California, CA, USA Jeremy D. Schmahmann Ataxia Unit, Cognitive and Noriyuki Koibuchi Behavioral Neurology Unit Department of Integrative Physiolgy Department of Neurology Gunma University Graduate School of Massachusetts General Hospital Medicine Harvard Medical School Maebashi, Gunma, Japan Boston, MA, USA Ferdinando Rossi Neuroscience Institute of the Cavalieri-Ottolenghi Foundation (NICO) University of Turin Orbassano, Turin, Italy ISBN 978-94-007-1332-1 ISBN 978-94-007-1333-8 (eBook) ISBN 978-94-007-1404-5 (print and electronic bundle) DOI 10.1007/978-94-007-1333-8 Springer New York Heidelberg Dordrecht London Library of Congress Control Number: 2012942646 # Springer Science+Business Media Dordrecht 2013 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.
    [Show full text]
  • Assessing Mild Cognitive Impairment with Amyloid and Dopamine Terminal Molecular Imaging
    Journal of Nuclear Medicine, published on April 9, 2013 as doi:10.2967/jnumed.112.112599 Assessing Mild Cognitive Impairment with Amyloid and Dopamine Terminal Molecular Imaging Roger L. Albin1–4, James F. Burke1,3,5, Robert A. Koeppe6, Bruno Giordani4,7, Sid Gilman1, and Kirk A. Frey1,6 1Department of Neurology, University of Michigan, Ann Arbor, Michigan; 2Geriatrics Research, Education, and Clinical Center, VAAAHS, Ann Arbor, Michigan; 3Neurology Service, VAAAHS, Ann Arbor, Michigan; 4Michigan Alzheimer Disease Center, Ann Arbor, Michigan; 5Robert Wood Johnson Clinical Scholars Program, University of Michigan, Ann Arbor, Michigan; 6Department of Radiology, University of Michigan, Ann Arbor, Michigan; and 7Department of Psychiatry, University of Michigan, Ann Arbor, Michigan have a progressive course, and others may improve over We evaluated PET-based classification of neurodegenerative time (8–12). Clinical trials enrolling MCI subjects face pathology in mild cognitive impairment (MCI). Methods: Our the same challenge as trials involving subjects with early study was a cross-sectional and prospective evaluation of a co- dementias: the strong likelihood of enrolling heteroge- hort of 27 MCI subjects drawn from a university-based cognitive neous subject populations, plus the problem of enrolling disorders clinic. We compared expert clinical consensus clas- sification of MCI at entry and possible dementia at follow-up subjects who will not go on to develop dementia. The de- with molecular imaging–based classification using 11C-dihydo- velopment of PET ligands identifying characteristic patho- tetrabenazine PET measurement of striatal dopamine terminal logic features of different neurodegenerative dementias integrity and 11C-Pittsburgh compound B (11C-PiB) PET measure- offers the possibility of a minimally invasive subclassification ment of cerebral amyloid burden.
    [Show full text]
  • Cuaderno De Documentacion
    SECRETARIA DE ESTADO DE ECONOMIA Y APOYO A LA EMPRESA MINISTERIO DE ECONOMÍA Y DIRECCION GENERAL DE POLÍTICA ECONOMICA COMPETITIVIDAD '$' UNIDAD DE APOYO CUADERNO DE DOCUMENTACION Número 102.3 ANEXO IX Alvaro Espina 24 Noviembre de 2014 Entre 28 Septiembre y 7 de octubre ft.com Comment Opinion October 7, 2014 6:19 am Apple, the European Commission and Ireland By James Stewart A tax-based industrial policy will not produce an innovative economy, writes James Stewart ©Bloomberg Apple's campus in Cork, Ireland I rish tax policy has in recent years attracted considerable international criticism, but within Ireland it is seen as inviolable. Enda Kenny, the Irish prime minister, denies that the country has become a “brass plate location” where international corporations try to book their profits so as to benefit from low tax rates. He has described the country’s low tax rate as “a cornerstone of Irish industrial policy”. It is no doubt true that a sudden change of policy would hurt investment in the short term. What Ireland’s government seems not to be aware of, however, is the vast quantity of profits that are not subject to corporation tax anywhere in the world because of “double Irish” tax strategies. More ON THIS STORY// Apple braced for explosive Brussels probe/ Apple hit by Brussels tax finding/ Apple hits back over ‘bendgate’ furore/ Lex iPhone 6 – bent phone, firm margin/ New iPhones the verdict ON THIS TOPIC// Cork brushes off Apple tax claims/ Ireland under pressure over low tax rates/ Q&A Brussels tackles Ireland over Apple tax/ Watchdog warns Ireland over budget IN OPINION// Joe Studwell Focus on Hong Kong tycoons/ Amy Kazmin India’s clean-up drive/ Anjana Ahuja The fight against Ebola/ Dominique de Villepin Weapons of peace This ruse involves two Irish companies, one of which makes sales to customers and pays hefty royalties to the second, which is resident in a tax haven such as the Cayman Islands.
    [Show full text]
  • View a Copy of Gilman's CV
    Sid Gilman, M.D., F.R.C.P. William J. Herdman Distinguished University Professor of Neurology Director, Michigan Alzheimer’s Disease Research Center 300 N. Ingalls Street, Room 3D15, SPC 5489 734-936-1808 [email protected] Title and Contents Page 1 Education and Training Page 2 Certification and Licensure Page 2 Academic, Administrative, and Clinical Appointments Page 2 Research Interests Page 3 Grants Page 3 Honors and Awards Page 5 Memberships in Professional Societies Page 5 Editorial Positions, Boards, and Peer-Review Service Page 6 Teaching Page 9 Committee, Organizational, and Volunteer Service Page 9 Consulting Positions Page 9 Visiting Professorships, Seminars, and Extramural Invited Presentations Page 10 Bibliography Page 11 Sid Gilman, M.D., F.R.C.P. 1/12/2011 1 Sid Gilman, M.D., F.R.C.P. William J. Herdman Distinguished University Professor of Neurology Director, Michigan Alzheimer’s Disease Research Center 300 N. Ingalls Street, Room 3D15, SPC 5489 734-936-1808 [email protected] Education and Training High School: 09/1947-06/1950 Huntington Park High School Huntington Park, CA Undergraduate: 09/1950-06/1953 College of Letters and Science University of California at Los Angeles 06/1954 Bachelor of Arts Medical School: 09/1953-06/1957 School of Medicine University of California at Los Angeles 06/1957 Doctor of Medicine Internship: 07/1957-06/1958 Internal Medicine, University of California Hospital, Los Angeles Research Training: 07/1958-06/1960 Research Associate in Neurophysiology, National Institute of Neurological Diseases
    [Show full text]
  • In Re Elan Corporation Securities Litigation 08-CV-08761-Amended
    Case 1:08-cv-08761-AKH Document 88 Filed 03/25/11 Page 1 of 54 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK X In re ELAN CORPORATION SECURITIES Master File No. 1:08-cv-08761-AKH LITIGATION CLASS ACTION This Document Relates To: : r°----^--- _ ALL ACTIONS. LE ' pg m^«kF—ty^ ^ ( ep _ s^ 0 ^-r Y 'N' 4 ^ H ^ t^ w'pry, : ^ rt alen ^( AMENDED CONSOLIDATED COMPLAINT FOR VIOLA '^ s S— f,^ ^{ L SECURITIES LAWS _ . Case 1:08-cv-08761-AKH Document 88 Filed 03/25/11 Page 2 of 54 INTRODUCTION AND OVERVIEW 1. This is a class action for violations of the anti-fraud provisions of the federal securities laws on behalf of all purchasers of Elan Corporation, plc (“Elan” or the “Company”) American Depository Receipts (“ADRs”) listed and trading on the New York Stock Exchange (“NYSE”) between May 21, 2007 and October 21, 2008 (the “Class Period”). 2. Elan is a neuroscience-based biotechnology company. During the Class Period, Elan’s biggest-selling drug was Tysabri, a treatment for multiple sclerosis. The future of Tysabri was threatened, however, as it had been removed from the market in February 2005 after two patients taking it died from a rare neurological disorder. Tysabri was back on the market by September 2006, but only pursuant to a rigorous program to monitor the drug for further side effects. By the start of the Class Period, sales of Tysabri had only slowly begun to recover. At the same time, the sales of a number of Elan’s other drugs were plummeting due to generic competition.
    [Show full text]